Abstract 3345
Background
Patients with advanced end stage cancer have < 1% chance of spontaneous circulation following cardiopulmonary resuscitation (CPR). Effective communication in a timely manner is best practice to ensure DNACPR (Do not attempt cardiopulmonary resuscitation) decisions are implemented correctly, well understood by patients/relatives and to avoid unnecessary CPR. Previous audit data at LRI and clinician experience indicated that oncology inpatients were having significant delays in DNACPR discussions. In many cases DNACPR decisions were occurring in emergency clinical situations by out of hours on-call medical staff.
Methods
We identified unwell (early warning score >5) oncology inpatients admitted to LRI. Using a data collection tool, we primarily identified the proportion of patients who had a DNACPR decision. Furthermore, we analysed timeliness of DNACPR decisions, involvement of patients’ own oncology team and documentation of prognosis/escalation plans. Liaising with healthcare professionals from oncology & palliative care we formulated ideas to improve outcomes. Enhancing communication between permanent ward staff (nurses & junior doctors) and senior decision makers (oncology registrars & consultants) was vital to improve outcomes. We therefore empowered junior doctors/nursing staff to identify patients who needed DNACPR discussions using a proforma tool utilising board round meetings as a platform. Data was then analysed to compare outcomes.
Results
Qualitative data showed improved confidence for junior doctors in identifying & communicating DNACPR discussions.Table:
1598P
Before Intervention | After Intervention | |
---|---|---|
DNACPR discussed by own team | 11% | 54% |
DNACPR discussed by oncology team | 29% | 92% |
DNACPR discussed in daytime | 24% | 77% |
Mean time to implement DNACPR | 4 days | 2.5 days |
DNACPR implemented and patient discharged home | 5% | 54% |
DNACPR not implemented in eligible patient – died following CPR | 44% | 12% |
Documentation of escalation plan | 30% | 85% |
Documentation of prognosis | 25% | 54% |
Conclusions
Empowering junior doctors and simple departmental changes lead to a significant improvement in communicating and implementing DNACPR decisions. We therefore significantly reduced unnecessary CPR attempts and subsequently improved communication and documentation of escalation plans and prognosis. We believe our model can be implemented in other oncology centres and look forward to discussing this further.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Health Service, UK.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5437 - Salivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: possible relationship with oral mucositis
Presenter: Luciana Corrêa
Session: Poster Display session 1
Resources:
Abstract
1483 - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
Presenter: Toshihide Yokoyama
Session: Poster Display session 1
Resources:
Abstract
2047 - Taste and smell alterations (TSAs) in patients (pts) with stage II-III colon cancer (CC): a pilot within the PROTECT study
Presenter: Jeroen Derksen
Session: Poster Display session 1
Resources:
Abstract
5984 - Clinical characteristics are associated with acupuncture treatment response for xerostomia in cancer patients
Presenter: Wenli Liu
Session: Poster Display session 1
Resources:
Abstract
2845 - Psychosocial Distress of Adolescent and Young Adults with Cancer at Diagnosis: A Case-Matched Retrospective Cohort of 2045 Patients in British Columbia.
Presenter: Alannah Smrke
Session: Poster Display session 1
Resources:
Abstract
724 - Accuracy of distress thermometer to measure cancer-related mood disorders in Chinese patients with cancer
Presenter: Sudip Thapa
Session: Poster Display session 1
Resources:
Abstract
2357 - Modalities of biosimilar filgrastim use in clinical practice in >1000 patients receiving chemotherapy regimens with a rest period of ≤14 days: the TOPAZE study
Presenter: Jean Marc Phelip
Session: Poster Display session 1
Resources:
Abstract
1426 - The Effect of Increasing Doses of Pegfilgrastim (Peg) on Thrombocytopenia (T) in Breast Cancer (BC) Patients (pts) Receiving Taxotere (Doc), Doxorubicin, Cyclophosphamide (TAC) and Plinabulin (Plin)
Presenter: Douglas Blayney
Session: Poster Display session 1
Resources:
Abstract
712 - The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing chemotherapy with or without radiotherapy
Presenter: Hikmat Abdel-Razeq
Session: Poster Display session 1
Resources:
Abstract
1496 - Randomized, double-blind, cross-over Phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references
Presenter: Maria Velinova
Session: Poster Display session 1
Resources:
Abstract